PRKN and Parkinson disease: Control iPSC lines CD12 and CC3 as well as iPSC line SM14, from a preclinical PD patient carrying compound heterozygous loss-of-function mutations in PARK2 associated with familial early-onset PD [34–36], were differentiated to BMECs using E6 medium (Fig. 1).